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A B S T R A C T
Breast cancer (C50) and neoplasms of female genital organs (C51-C58) represent one of the most frequent cancer
groups among females in economically developed countries. The Institute of Public Health of the Osijek-Baranja County
in collaboration with different county institutes provide updated information on the cancer occurrence and trends in the
Osijek-Baranja County (OBC). The aim of this article is to provide information on the tendencies relating to these cancer
groups in the OBC during the period from 2001 to 2009, which will be the first report on these cancer sites on a county
level in Croatia. This article processes data on cancer incidence and mortality, appertaining age distribution, median
age, cancer survival and length of stay in the county hospitals collected in period 1996–2010. In the OBC, the overall inci-
dence rates of breast, cervix uteri, corpus uteri and ovary cancer were, using the EU standard population, 82.9, 13.0, 19.0
and 14.5/100,000, respectively, and are all characterized by a declining tendency in the second period except breast can-
cer. The overall breast incidence rate resembles the Croatian average and way exceeds the corresponding Central and
Eastern Europe incidence rates, but is still bellow the Northern Europe ones. Also, the overall mortality rates of breast,
cervix uteri, corpus uteri and ovary cancer were 29.6, 5.0, 8.1 and 9.6/100,000, respectively, and are all featured by a in-
creasing tendency. The cancer 5-year relative survival rate from breast, cervix uteri, corpus uteri and ovary cancer in pe-
riod 2001–2005 amounted to 64.2%, 66.1%, 57.4% and 43.0%, respectively. The overall median ages at diagnosis of
breast, cervix uteri, corpus uteri and ovary cancer totalled 61.9, 56.4, 66.4 and 60.8 years, respectively, while the median
ages at death from these cancers were 68.7, 65.7, 70.3 and 67.6 years, respectively. During the entire 9-year period, the av-
erage length of stay in hospital due to breast, cervix uteri, corpus uteri and ovary cancer were 12.1, 14.8, 18.5 and 11.3
days, respectively. The length of stay in hospital decreased for all but for ovary cancer. Implementation and consolidation
of women’s awareness of these cancers and relating early diagnostic activities within the OBC population seem to be the
most effective ways to reduce the appertaining risks and thus to encourage changes in the lifestyle.
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In European females, breast cancer was the most
common cancer in the year 1995. It accounted for 26% of
all newly registered cancers and was the leading cause of
death in females. It was associated with 17% of all deaths
from cancer in females1. In 2012, the share of breast can-
cer in all female cancers amounted to 28.8% (94/100,000,
using the EU standard population) while its share in all
cancer deaths among females totalled 16.8% (23/100,000).
There were significant differences between certain Euro-
pean regions in this view, though. In Croatia, the breast
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cancer incidence and mortality rate were 83 and 25/
100,000, respectively (2004)2,3. The established risk fac-
tors for breast cancer refer to low age at menarche,
nulliparity, high age at first childbirth, short time from
last full-term pregnancy, oral contraceptive use, low phy-
sical activity, alcohol intake and obesity4. The 5-year rela-
tive survival rate from breast cancer among European fe-
males diagnosed in period 1995–1999 amounted to 79%5.
The basic factors affecting survival rate from breast can-
cer include stage at diagnosis, availability and quality of
treatment, screening programmes and low socioecono-
mic status6–8. Comparing period 1990–1994 with period
2000–2004, the breast cancer mortality in the EU de-
clined from 20.8 to 18.1/100,000 (–13%) at all age. The
biggest decline, from 16.7 to 12.6/100,000 (–25%), was
registered among females of the 35–44 age group9 mainly
due to improved treatment with anti-estrogens and che-
motherapy as well as due to the impact of screening
mammography10,11. According to the 2012 data, the mor-
tality rate in the EU increased to 21.1/100,00012. In the
USA, the age distribution of breast cancer incidence is
disclosed by the fact that more then 2/3 of all breast can-
cer cases were aged from 45 to 74 and they were almost
equally distributed between age groups 45–54, 55–64 and
65–74 (peak incidence appeared in the 55–64 age group).
In the same country, the age distribution of death from
breast cancer was characterized by a shift of 10 years
into an older age. More than 2/3 of death cases occurred
within the 55–84 age group, with most deaths in the
75–84 age group13. In the USA, the median ages at diag-
nosis and at death amounted to 61 and 68 years, respec-
tively13. The median age at breast cancer diagnosis in
Croatia was around 62 years in 200514.
Ovarian and endometrial cancer
The epidemiology of both ovarian and endometrial
cancer is closely intertwined. The same personal risk fac-
tors (late menarche, early age at first birth, breastfeed-
ing, oral contraceptives) can be attributed to the occur-
rence of either of these cancers. The incidence rates of
endometrial and ovarian cancer in Europe totals 10.4
and 8.4/100,000 in Southern Europe and 14.6 and 11.8/
100,000 in Central and Eastern Europe and Northern
Europe, respectively.
The mortality rate from endometrial cancer ranges
from 1.8 to 3.4/100,000, and from ovarian cancer from
4.2 to 5.5/100,00015,16. The endometrial and ovarian can-
cer incidence rates increased sharply during the perime-
nopausal years and reach peak well after the menopause.
The endometrial cancer incidence rates drop after age
70, but the ovarian cancer incidence rates continue to
rise with aging13. In Denmark and the USA, the median
age of patients at diagnosis of these two cancers is be-
tween 61 and 64 years17,18.
In the USA, the survival rates from ovarian cancer
mostly vary according to age, disease stage and kind of
treatment. The early disease stage is featured by a 5-year
survival rate above 70%, but only 15% for those diag-
nosed in the advanced disease stage. Younger women di-
agnosed with this cancer combat the disease more easily
than older women and hence the former manage to stay
alive longer on average. The 5-year relative survival rate
at diagnosis in females aged 15–39 is nearly 70%. On the
other hand, this rate is only 12% for females over 8019.
The mean age-adjusted 5-year relative survival rate from
ovarian cancer is highest in Nordic countries (36.3%, ex-
cept Denmark) and Central Europe, intermediate in Sou-
thern Europe and lowest in Eastern Europe19.
In Europe, the 5-year relative survival rate at diagno-
sis from endometrial cancer was lower among patients
aged 65 to 74 (78%) compared with approximately 90%
among patients under 6520.
Cervical cancer
The overall incidence rate of cervical cancer in Eu-
rope is 10.6/100,000. A significantly lower rate has been
found in Western Europe. It is accompanied with a down-
ward trend (more advanced prevention programmes). On
the other hand, Central and Eastern European countries
are marked with a significantly higher incidence rate (in
correlation to the intensity of organized screening)21–23.
In Europe in general, the incidence rate of cervical can-
cer varies between 6.9/100,000 in Western Europe to
14.7/100,000 in Central and Eastern Europe and North-
ern Europe. The mortality rate from cervical cancer in
Europe ranges from 2/100,000 in Western Europe to
6.2/100,000 in Central and Eastern Europe15. In Croatia,
the incidence rates of cervical cancer in 2006 were 13.4/
100,000 (using the EU standard population) and 10.6/
100,000 (using the world standard population)24. The
mortality rates from cervical cancer declined in most Eu-
ropean countries between 2000 and 2010 (4.8 and 4/
100,000, respectively). This does not apply to Bulgaria,
the Former Yugoslav Republic of Macedonia, Croatia,
Greece and Ireland. The mortality rate in Croatia went
up in the same period25. In 2004, the mortality rate in
Croatia totalled 12.7/100,00026. The 5-year relative sur-
vival rate from cervical cancer diagnosed between 1995
and 1999 in European countries was 62.6 years5. The Eu-
ropean Union achieved, in periods 1997–2002 and 2004–
2009, minor progress with respect to the 5-year survival
rates from cervical cancer, but this progress was not uni-
form across countries25. In the USA, the median age at
diagnosis of cervical cancer in all females was 48 years
and the median age at death was 57 years, based on the
2004 to 2008 SEER data13.
In the USA, the mean length of stay in hospital con-
cerning females with gynaecologic cancer with comorbid
medical conditions or with postoperative complication
(8.6 days and 11.9 days) in surgery departments was sig-
nificantly longer then the length of stay in females with
neither comorbid medical condition nor postoperative
complication27.
The aim of this study is to describe and compare data
for malignant neoplasm of breast (C50) and the data on
malignant neoplasms of female genital organs (C51-C58)
with the demographic (gender, age, median age) and sta-
tistical features of the referring cancer patients (inci-
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dence and mortality rate, survival rate, length of stay in
hospital) and is focused on obtaining information on the
status of this group of cancer in the OBC in relation to
the corresponding status of this disease in Croatia and
Europe in period 2001–2009.
Materials and Methods
Data source
Although the representativeness of their data might
be challenged, mandatory county hospitals data reports,
county bureaus of statistics and the County Register of
Deaths still represent the only available source of infor-
mation on the profile of cancer in the OBC. All data from
the 2001–2009 period originate from these institutions.
The cohort studied in this article included all people with
cancer who were registered as the patients in one of two
hospitals in the OBC in the time period from 1996 to
2010. Based on these sources, a database of people who
were hospitalized in the area of the OBC for any reason
whatsoever (including cancer) has been generated28,29.
The data on each of the hospitalized patients have been
supplemented with data obtained from the Register of
Deaths.
Data on every person with cancer are accompanied
with their chronological order of illness and hospitaliza-
tion. The database involved all hospitalizations and all
data on ONKO or BSL forms (mandatory statistical pat-
terns for all hospitalized patients in Croatia). The ONKO
form is a mandatory statistical report on every hospital-
ized cancer patients in Croatia. The BSL form is a man-
datory statistical report on every hospitalized person,
regardless of the causes of hospitalization. All cancer pa-
tients coming from this area are hospitalized in state-
-owned (public) hospitals since there are still the only
hospitals here.
Statistical analysis
The cancers were classified according to the Interna-
tional Statistical Classification of Diseases and Related
Health Problems (ICD-10), codes C50 and C51-C58. The
cancer incidence and mortality estimates in the period
from 2001 to 2009 were prepared for all cancers based on
gender and for age groups 0–19, 20–44, 45–64, 65+ by
the year at cancer diagnosis. Based on the 2001 census,
the analysis covered a total population of 330.506 people
in the OBC. The Croatian National Health Insurance is a
universal health insurance that covers all or almost all
costs (depending on a personal choice of the type of in-
surance) of treatment of Croatia citizens and provides
them with the same chances of recovery. Therefore, this
article can be said to comprise the entire population of
cancer patients treated in the OBC.
Age-standardized rates were calculated as the num-
ber of new cases (incidence) or deaths (mortality) in spe-
cific age groups per 100,000 persons each year, and were
age-adjusted to the EU standard population.
Descriptive statistics were used for both age and gen-
der. The survival rates denote the outcome up to 5 years
after diagnosis. This applies to cancer patients who were
diagnosed with cancer during the 2001–2005 period. All
survival estimates were age-adjusted on the basis of four
age groups. The analyses were conducted using age-spe-
cific rates, the age-standardization-direct method and
95% confidence intervals (95% CI). The standardized in-
cidence and mortality ratios as well as the 95% confi-
dence intervals were computed for C50 and C51-C58 pur-
suant to the year at cancer diagnosis. Also, both ratios
were stratified according to the year at cancer diagnosis,
age and gender. The median age is the observation ran-
ked in the middle; that is 50% of patients are diagnosed
at an older age and 50% are diagnosed at a younger age
compared to the median. The EU standard population
was used in the analysis30. The length of stay was deter-
mined according to the date of admission and to the date
of discharge with regard to the index admission. The SAS
statistical package (version 9.1, SAS Institute INC, Cary,
NC, USA) was used for the statistical analysis31 and
Microsoft® Office Excel® 2007.
Results
Median age
The overall median ages at diagnosis (OMADg) and at
death (OMAD) from breast cancer (C50) were 61.8 and
69.4 years, respectively (Tables 1 and 2). The difference
between the overall OMADg and OMAD was 7.6 years.
The both indicators showing not significant upward mo-
derate trendlines, R2=0.308 and R2=0.143, respectively.
Concerning female patient of 65+ years (Table 1), there
was significant strong OMADg upward trendline for the
whole group of malignant neoplasms, C00-C96 as well as
for malignant neoplasm of cervix uteri, C53 (R2=0.688,
t(7)=3.928, p<0.01 and R2=0.834, t(7)=5.930, p<0.01,
respectively). Among all cancer sites C50-C58 for all age
groups, only C53 (OMADg=55.6 years) showed signifi-
cant strong upward trendline (R2=0.759, t(7)=4.695,
p<0.01). With regard to cancer sites cervix uteri (C53),
corpus uteri (C54) and ovary cancer (C56) OMADg were
55.6, 65.2 and 61.0 years, respectively. The difference be-
tween the OMADg and OMAD from these cancer sites
were 9.8, 6.4 and 6.4 years, respectively.
Concerning female patient of 65+ years (Table 2),
there were significant strong OMAD upward trendlines
for malignant neoplasm of breast (C50, R2=0.565, t(7)=
3.015, p<0.02) and for malignant neoplasm of corpus
uteri (C54, R2=0.529, t(7)=2.803, p<0.05). Cancer sites
C53, C54 and C56 were marked with the OMAD of 65.4,
71.6 and 67.4 years, respectively (Table 2).
Incidence and mortality rate
Tables 3 and 4 show the overall age-standardized inci-
dence (OIR) and mortality rates (OMR) from breast cancer
(C50) and cancers of female genital organs (C51-C58). In
the entire 9-year period, 12 males were diagnosed with
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TABLE 1
THE MEDIAN AGE AT DIAGNOSIS FOR MALIGNANT NEOPLASMS OF BREAST AND FEMALE GENITAL ORGANS (C50, C51-C58)
IN THE OBC, PERIOD 2001–2009






61.9 y=61.09x0.008, R²=0.168 UW moderate –
C51 66.6 y=64.24x0.029, R²=0.044 UW weak –
C52 63.7 y=70.67x–0.06, R²=0.055 DW weak –
C53 55.6 y=47.63x0.103, R²=0.759 UW strong t(7)=4.695, p<0.01
C54 65.2 y=62.29x0.034, R²=0.272 UW moderate –
C55 71.0 y=76.36x–0.11, R²=0.097 DW weak –
C56 61.0 y=62.09x–0.01, R²=0.065 DW weak –
C57 67.2 y=34.44x0.428, R²=0.701 UW strong –
C58 51.3 N/A – – –
C51-C58 61.7 y=59.63x0.024, R²=0.28 UW moderate –
C50-C58 61.8 y=60.49x0.014, R²=0.308 UW moderate –
C50 20–44 39.4 y=40.12x–0.01, R²=0.092 DW weak –
45–64 55.7 y=55.34x0.003, R²=0.030 UW barely –
65+ 73.3 y=73.26x0.000, R²=0.005 UW barely –
C51 20–44 38.6 y=43.00x–0.09, R²=0.176 DW moderate –
45–64 54.9 y=53.85x0.018, R²=0.066 UW weak –
65+ 76.8 y=76.18x–1E–0, R²=0.000 DW barely –
C52 20–44 36.8 N/A – – –
45–64 57.0 y=69.27x–0.11, R²=0.105 DW weak –
65+ 77.1 y=72.73x0.042, R²=0.228 UW moderate –
C53 0–19 19.6 N/A – – –
20–44 36.0 y=35.83x0.002, R²=0.000 UW barely –
45–64 54.1 y=55.84x–0.02, R²=0.310 DW moderate –
65+ 73.9 y=67.91x0.051, R²=0.834 UW very strong t(7)=5.930, p<0.01
C54 20–44 36.7 y=37.58x–0.01, R²=0.018 DW barely –
45–64 56.9 y=56.81x0.001, R²=0.001 UW barely –
65+ 73.7 y=72.09x0.016, R²=0.279 UW moderate –
C55 20–44 38.5 N/A – – –
65+ 74.6 y=73.28x0.018, R²=0.158 UW weak –
C56 0–19 6.5 y=0.161x2.372, R²=0.254 UW moderate –
20–44 36.4 y=34.13x0.046, R²=0.052 UW weak –
45–64 55.5 y=54.02x0.018, R²=0.389 UW moderate –
65+ 73.5 y=73.42x0.000, R²=8E–05 DW barely –
C57 45–64 55.6 N/A – – –
65+ 78.8 y=187.6x–0.48, R²=0.702 DW strong –
C58 45–64 51.3 N/A – – –
C51-C58 0–19 9.8 y=5.756x0.033, R²=4E–05 DW barely –
20–44 36.4 y=36.09x0.008, R²=0.012 UW barely –
45–64 55.7 y=55.77x–1E–0, R²=0.019 DW barely –
65+ 73.9 y=72.35x0.015, R²=0.688 UW strong t(7)=3.928, p<0.01
C50-C58 0–19 9.8 y=5.756x0.033, R²=4E–05 DW barely –
20–44 38.0 y=36.09x0.008, R²=0.012 UW barely –
45–64 55.7 y=55.77x–1E–0, R²=0.019 DW barely –
65+ 73.6 y=72.35x0.015, R²=0.688 UW strong t(7)=3.928, p<0.01
COD(S) – Coefficient of determination (strength), OMADg – overall median age at diagnosis, period 2001–2009, ICD10 – International
Statistical Classification of Diseases and Related Health Problems, 10th Revision, N/A – not available, DW – downward trendline, UW
– upward trendline, R – Relationship, df – degrees of freedom, »–« – to small data number or no significant (p>0.05)
C50 cancer (overall incidence rate was 0.8/100,000), and
8 males died from this cancer in the same period (overall
mortality rate was 0.5/100,000). This data are not pro-
cessed in this article though.
The OIR and OMR for breast cancer (C50) in the en-
tire period were 82.9/100,000 (SD±6.48, CI 70.2–95.6)
and 29.6/100,000 (SD±3.64, CI 22.46–36.73), respecti-
vely. The OIR is featured by non significant barely down-
ward trendline while OMR showed significant strong up-
ward trendline (R2=0.656, t(7)=3.653, p<0.01). Concer-
ning the OIR in females diagnosed with C50 (Table 3),
there was insignificant upward trendlines in age groups
45–64 and 65+ years (R2=0.012 and R2=0.015, p>0.05,
respectively) and median downtrend trendlines in age
group 20–44 years (R2=0.280, p>0.05). Concerning the
OMR (Table 4), there was strong significant upward
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TABLE 2
THE MEDIAN AGE AND AT DEATH FOR MALIGNANT NEOPLASMS OF BREAST AND FEMALE GENITAL ORGANS (C50, C51-C58)
IN THE OBC, PERIOD 2001–2009






69.6 y=67.65x0.022, R²=0.434 UW moderate –
C51 77.5 y=70.08x0.055, R²=0.17 UW moderate –
36 C52 59.9 N/A – – –
C53 65.4 y=62.59x0.025, R²=0.172 UW moderate –
C54 71.6 y=67.21x0.043, R²=0.384 UW moderate –
C55 71.0 y=79.21x–0.13, R²=0.142 DW weak –
C56 67.4 y=70.03x–0.02, R²=0.440 DW moderate –
C57 69.3 y=54.82x0.139, R²=0.241 UW moderate –
C51-C58 69.1 y=67.89x0.010, R²=0.088 UW weak –
C50-C58 69.4 y=67.47x0.018, R²=0.275 UW moderate –
C50 20–44 41.3 y=42.34x–0.02, R²=0.074 DW weak –
45–64 56.3 y=56.72x–0.00, R²=0.011 DW barely –
65+ 76.5 y=74.80x0.014, R²=0.565 UW strong t(7)=3.015, p<0.02
C51 45–64 57.2 N/A – – –
65+ 79.0 y=79.60x–0.00, R²=0.000 DW barely –
C52 45–64 59.9 N/A – – –
C53 20–44 39.2 y=39.78x–0.00, R²=0.019 DW barely –
45–64 55.1 y=55.60x–0.00, R²=0.001 DW barely –
65+ 75.3 y=71.58x0.027, R²=0.243 UW moderate –
C54 20–44 36.5 y=21.27x0.342, R²=0.997 UW very strong t(1)=18.23, p<0.01
45–64 57.9 y=58.80x–0.01, R²=0.143 DW weak –
65+ 76.0 y=72.96x0.026, R²=0.529 UW strong t(7)=2.803, p<0.05
C55 20–44 38.5 N/A – – –
65+ 74.7 y=74.52x0.006, R²=0.014 UW barely –
C56 20–44 35.4 y=36.79x–0.01, R²=0.015 DW barely –
45–64 56.2 y=54.16x0.016, R²=0.034 UW weak –
65+ 74.5 y=74.44x0.000, R²=0.000 UW barely –
C57 45–64 51.1 N/A – – –
65+ 73.0 y=67.05x0.047, R²=0.083 UW weak –
C51-C58 20–44 37.2 y=36.54x0.001, R²=0.000 UW barely –
45–64 56.4 y=57.25x–0.01, R²=0.268 DW moderate –
65+ 75.5 y=73.51x0.017, R²=0.438 UW moderate –
C50-C58 20–44 39.3 y=39.93x–0.01, R²=0.121 DW weak –
45–64 56.3 y=56.93x–0.00, R²=0.064 DW weak –
65+ 76.1 y=74.11x0.016, R²=0.693 UW strong t(7)=3.975, p<0.01
COD(S) – Coefficient of determination (strength), OMAD – overall median age at death, period 2001–2009, ICD10 – International Sta-
tistical Classification of Diseases and Related Health Problems, 10th Revision, N/A – not available, DW – downward trendline, UW –
upward trendline, R – Relationship, df – degrees of freedom, »–« – to small data number or no significant (p>0.05)
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TABLE 3
THE OVERALL AGE-STANDARDIZED INCIDENCE RATE (OIR) IN THE OBC FOR MALIGNANT NEOPLASMS OF BREAST AND FEMALE
GENITAL ORGANS (C50, C51-C58) PER 100,000 USING EU STANDARD POPULATION, PERIOD 2001–2009






82.9 y=82.18x0.001, R²=7E–05 DW barely –
C51 1.9 y=1.450x0.025, R²=0.000 UW barely –
C52 0.5 y=0.341x0.319, R²=0.192 UW moderate –
C53 13.0 y=11.69x0.061, R²=0.050 UW weak –
C54 19.0 y=25.13x–0.21, R²=0.407 DW moderate –
C55 0.4 y=0.796x–0.05, R²=0.051 DW weak –
C56 14.5 y=17.97x–0.16, R²=0.230 DW moderate –
C57 0.3 y=7.106x–1.52, R²=0.773 DW strong t(2)=2.609, p<0.05
C58 0.1 N/A – – –
C51-C58 49.6 y=57.44x–0.10, R²=0.410 DW moderate –
C50-C58 132.5 y=139.6x–0.03, R²=0.109 – N/A –
C50 20–44 25.3 y=31.03x–0.15, R²=0.280 DW moderate –
45–64 182.7 y=177.6x0.016, R²=0.012 UW barely –
65+ 257.5 y=245.3x0.026, R²=0.015 UW barely –
C51 20–44 0.6 N/A – – –
45–64 2.9 y=4.353x–0.17, R²=0.085 DW weak –
65+ 8.5 y=5.9x0.079, R²=0.005 UW barely –
C52 20–44 0.2 N/A – – –
45–64 1.0 y=2.346, R²=#N/A UW – –
65+ 1.4 y=3.178, R²=#N/A UW – –
C53 20–44 11.6 y=19.40x–0.42, R²=0.384 DW moderate –
45–64 22.9 y=13.51x0.248, R²=0.048 UW weak –
65+ 29.0 y=12.36x0.525, R²=0.566 UW strong t(7)=3.021, p<0.02
C54 20–44 4.1 y=8.983x–0.33, R²=0.186 DW moderate –
45–64 35.7 y=45.18x–0.20, R²=0.184 DW moderate –
65+ 78.8 y=88.00x–0.09, R²=0.089 DW weak –
C55 20–44 0.2 N/A – – –
65+ 3.2 y=7.135x–0.01, R²=0.002 DW barely –
C56 0–19 0.8 y=2.519, R²=–3E–1 DW barely –
20–44 5.2 y=9.258x–0.33, R²=0.170 DW moderate –
45–64 29.5 y=35.65x–0.14, R²=0.307 DW moderate –
65+ 46.3 y=68.41x–0.33, R²=0.254 DW moderate –
C57 45–64 0.8 N/A – – –
65+ 1.1 y=3.178, R²=1E–15 DW barely –
C58 45–64 0.3 N/A – – –
C51-C58 0–19 0.8 y=2.519, R²=–3E–1 DW barely –
20–44 21.8 y=35.65x–0.43, R²=0.312 DW moderate –
45–64 93.1 y=101.7x–0.07, R²=0.093 DW weak –
65+ 168.1 y=180.3x–0.05, R²=0.069 DW weak –
C50-C58 0–19 0.8 y=2.519, R²=–3E–1 DW barely –
20–44 47.1 y=65.94x–0.26, R²=0.430 DW moderate –
45–64 275.8 y=281.5x–0.01, R²=0.023 DW barely –
65+ 425.6 y=425.1x–0.00, R²=0.000 DW barely –
COD(S) – Coefficient of determination (strength), OIR – overall incidence rate, period 2001–2009, ICD10 – International Statistical
Classification of Diseases and Related Health Problems, 10th Revision, N/A – not available, DW – downward trendline, UW – upward
trendline, R – Relationship, df – degrees of freedom, »–« – to small data number or no significant (p>0.05)
trendline in age group 65+ years (R2=0.676, t(7)=3.821,
p<0.01).
The OIR and OMR from female genital organs (C51-
C58) were 49.6 (SD±4.99, CI 39.86–59.42) and 24.7/
100,000 (SD±3.3, CI 18.23–31.16), respectively (Tables 3
and 4). The changes in the OMR considering this group
of cancer have the opposite trends to the C50. Non signif-
icant downward OIR trendline is a moderate (R2=0.410,
p>0.05) while a significant upward OMR trendline is a
strong (R2=0.707, t(7)=4.109, p<0.01). Due to the both
OIR and OMR, the most common cancer sites within the
C51-C58 cancer group were malignant neoplasms of the
cervix uteri (C53, 13.0 and 5.0/100,000, respectively),
malignant neoplasms of the corpus uteri (C54, 19.0 and
8.1/100,000, respectively) and malignant neoplasms of
the ovary (C56, 114.5 and 9.6/100,000, respectively).
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TABLE 4
THE OVERALL AGE-STANDARDIZED MORTALITY RATE (OMR) IN THE OBC FOR MALIGNANT NEOPLASMS OF BREAST
AND FEMALE GENITAL ORGANS (C50, C51-C58) PER 100,000 USING EU STANDARD POPULATION, PERIOD 2001–2009






29.6 y=21.22x0.222, R²=0.656 UW strong t(7)=3.653, p<0.01
C51 1.2 y=0.460x0.517, R²=0.302 UW moderate –
C52 0.1 N/A – – –
C53 5.0 y=2.299x0.471, R²=0.412 UW moderate –
C54 8.1 y=5.704x0.214, R²=0.199 UW moderate –
C55 0.4 y=0.370x0.376, R²=0.422 UW moderate –
C56 9.6 y=9.299x0.014, R²=0.003 UW barely –
C57 0.3 y=0.482x–0.14, R²=0.172 DW moderate –
C51-C58 24.7 y=19.39x0.163, R²=0.707 UW strong t(7)=4.109, p<0.01
C50-C58 54.3 y=40.76x0.194, R²=0.871 UW very strong t(7)=6.874, p<0.01
C50 20–44 3.3 y=2.127x0.308, R²=0.165 UW moderate –
45–64 44.3 y=39.90x0.052, R²=0.021 UW barely –
65+ 157.9 y=96.04x0.325, R²=0.676 UW strong t(7)=3.821, p<0.01
C51 45–64 0.3 N/A – – –
65+ 9.9 y=4.254x0.429, R²=0.166 UW moderate –
C52 45–64 0.5 N/A – – –
C53 20–44 1.5 y=3.280x–0.26, R²=0.356 DW moderate –
45–64 8.3 y=3.234x0.590, R²=0.620 UW strong t(7)=3.379, p<0.02
65+ 21.2 y=9.803x0.459, R²=0.374 UW moderate –
C54 20–44 1.0 y=0.995x0.676, R²=0.394 UW moderate –
45–64 7.6 y=5.918x0.126, R²=0.016 UW barely –
65+ 53.7 y=35.82x0.253, R²=0.332 UW moderate –
C55 20–44 0.2 N/A – – –
65+ 3.2 y=3.291x0.432, R²=0.469 UW moderate –
C56 20–44 1.7 y=1.570x0.189, R²=0.118 UW weak –
45–64 14.9 y=7.363x0.439, R²=0.517 UW strong t(7)=2.737, p<0.05
65+ 48.4 y=59.08x–0.18, R²=0.126 DW weak –
C57 45–64 0.3 N/A – – –
65+ 1.8 y=3.178, R²=–3E–1 DW barely –
C51-C58 20–44 4.4 y=5.081x–0.10, R²=0.021 DW barely –
45–64 31.8 y=18.23x0.349, R²=0.428 UW moderate –
65+ 138.1 y=119.5x0.093, R²=0.185 UW moderate –
C50-C58 20–44 7.7 y=5.763x0.088, R²=0.009 UW barely –
45–64 76.1 y=59.10x0.165, R²=0.371 UW moderate –
65+ 296.0 y=214.8x0.213, R²=0.644 UW strong t(7)=3.558, p<0.01
COD(S) – Coefficient of determination (strength), OMR – overall mortality rate, period 2001–2009, ICD10 – International Statistical
Classification of Diseases and Related Health Problems, 10th Revision, N/A – not available, DW – downward trendline, UW – upward
trendline, R – Relationship, df – degrees of freedom, »–« – to small data number or no significant (p>0.05)
These three cancer sites comprise 86.1% of cancer in this
group. Therefore, remaining cases of cancer within this
group are not discussed in this article due to their small
number. Concerning the OIR in females diagnosed with
C51-C58, there were strong upward trendlines for C53 in
age group 65+ years and moderate one for age group
45–64 years (R2=0.566 and R2=0.384, respectively); for
cancer sites C54 and C56 there were weak or moderate
downward trendlines.
Concerning the OMR, there was strong upward trend-
line for malignant neoplasms of the cervix uteri (C53) in
age group 45–64 years (R2=0.620, t(7)=3.379, p<0.02,
Table 4), moderate for C53 and C54 in age 65+ years
(R2=0.374 and R2=0.332, respectively); a strong down-
ward trendline for C56 in the age of group 45–64 (R2=
0.517, t(7)=2.737, p<0.05) and weak one in the age of
group 65+ (R2=0.126).
Among sites of the C51-C58 cancer group (and well
below breast cancer incidence rate), malignant neo-
plasms of the corpus uteri (C54) were characterized by
the highest overall incidence rate of 19.0/100,000 (SD±
3.02, CI 13.09–24.93, Table 3). This cancer site showed a
moderate downward trendline (R2=0.407), more pro-
nounced in the age 45–64 (R2=0.184) years then in the
age 65+ (R2=0.089). Also, the incidence rate of malig-
nant neoplasm of ovary (C56, overall incidence rate was
14.5/100,000, SD±2.72, CI 9.19–19.85) had a moderate
downward trendline (R2=0.230) as well as it were in all
age groups. Unlike the incidence rates of malignant
neoplasms of the ovary and the corpus uteri, the inci-
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TABLE 5
THE 5-YEARS RELATIVE SURVIVAL RATES FOR MALIGNANT NEOPLASMS OF BREAST AND FEMALE GENITAL ORGANS (C50, C51-C58)
IN THE OBC, PERIOD 2001–2005
TABLE 5A. The age group percentage of relative survival rates (number of survival cases)
ICD-10 0–19 20–44 45–64 65+ All ages
C50 – – 76.8 (66) 76.4 (304) 49.9 (171) 64.2 (541)
C51 – – 100.1 (5) 75.8 (3) 35.5 (5) 54.9 (13)
C52 – – – – 50.5 (1) 106.6 (2) 76.0 (3)
C53 100.1 (1) 79.6 (31) 66.6 (29) 50.2 (16) 66.1 (77)
C54 – – 77.9 (14) 75.8 (63) 43.8 (51) 57.4 (128)
C55 – – – – – – 0.0 – 0.0 –
C56 100.1 (3) 80.1 (12) 57.1 (39) 20.4 (14) 43.0 (68)
C57 – – – – 67.4 (2) 106.6 (1) 76.0 (3)
C51-C58 100.1 (4) 80.6 (62) 67.2 (137) 37.1 (89) 54.5 (292)
C50-C59 100.1 (4) 78.6 (128) 73.3 (441) 44.6 (260) 60.4 (833)
TABLE 5B. Relative survival trend
Years
ICD-10 2001 2002 2003 2004 2005 COD(S) Trendline Strength Trend t-Test
C50 62.2 61.0 67.5 67.3 61.9 y=61.70x0.034,R²=0.180 UW moderate t(3)=0.811, p>0.05
C51 100.1 0.0 33.8 40.5 76.0 – – – N/A
C52 100.1 – 101.3 0.0 101.3 – – – N/A
C53 80.1 50.6 70.9 76.0 52.4 y=72.75x–0.12,R²=0.127 DW weak t(3)=0.660, p>0.05
C54 62.3 66.9 44.0 52.0 56.6 y=63.10x–0.12,R²=0.251 DW moderate t(3)=1.002, p>0.05
C55 0.0 – 0.0 – 0.0 – – – N/A
C56 38.9 41.0 54.5 42.2 41.1 y=40.62x0.065,R²=0.096 UW weak t(3)=0.564, p>0.05
C57 – – 50.6 – 101.3 – – – N/A
C51-C58 59.2 54.0 50.6 54.5 52.5 y=57.79x–0.06,R²=0.569 DW strong t(3)=1.990, p>0.05
C50-C59 61.0 58.0 61.3 62.9 58.1 y=60.39x–0.00,R²=0.002 DW barely t(3)=0.077, p>0.05
»–« – no cases, 0 – no survival cases, COD(S) – Coefficient of determination (strength), N/A – not available
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TABLE 6
THE AGE DISTRIBUTION AT DIAGNOSIS FOR MALIGNANT NEOPLASMS OF BREAST AND FEMALE GENITAL ORGANS
(C50, C51-C58) IN THE OBC, PERIOD 2001–2009
TABLE 6A. Age group distribution (%) at diagnosis for cancer sites C50-C58
ICD-10 Age group OIR COD(S) Trendline Strength Trend t-Test
C50 20–44 9.2 y=11.76x–0.19, R²=0.355 DW moderate –
45–64 47.3 y=46.46x0.013, R²=0.031 UW weak –
65+ 43.6 y=41.87x0.024, R²=0.076 UW weak –
C51 20–44 13.2 y=30.12x–0.26, R²=0.402 DW moderate –
45–64 23.7 y=26.89x0.075, R²=0.008 UW barely –
65+ 63.2 y=55.67x0.043, R²=0.004 UW barely –
C52 20–44 11.1 N/A – – –
45–64 44.4 y=1230x–1.65, R²=0.527 DW strong –
65+ 44.4 y=103.5x–0.23, R²=0.182 DW moderate –
C53 0–19 0.4 N/A – – –
20–44 28.3 y=53.39x–0.49, R²=0.505 DW strong t(7)=2.672, p<0.05
45–64 37.0 y=29.52x0.083, R²=0.014 UW barely –
65+ 34.3 y=14.98x0.511, R²=0.587 UW strong t(7)=3.154, p<0.02
C54 20–44 5.5 y=8.501x0.015, R²=0.000 UW barely –
45–64 38.6 y=37.02x0.013, R²=0.003 UW barely –
65+ 55.9 y=49.70x0.082, R²=0.143 UW weak –
C55 20–44 10.0 N/A – – –
65+ 90.0 y=100, R²=#N/A – – –
C56 0–19 1.1 y=6.142x–0.37, R²=0.416 DW moderate –
20–44 10.9 y=12.41x–0.00, R²=0.000 DW barely –
45–64 43.1 y=41.83x0.029, R²=0.012 UW barely –
65+ 44.9 y=49.96x–0.12, R²=0.11 DW weak –
C57 45–64 50.0 N/A – – –
65+ 50.0 y=1.838x2.112, R²=0.790 UW strong –
C58 45–64 100.0 N/A – – –
C51-C58 0–19 0.2 y=2.818x–1.32, R²=0.833 DW very strong –
20–44 4.9 y=7.358x–0.35, R²=0.245 DW moderate –
45–64 14.6 y=15.43x–0.04, R²=0.037 DW weak –
65+ 18.1 y=18.50x–0.02, R²=0.027 DW barely –
C50-C58 0–19 0.2 y=2.818x–1.32, R²=0.833 DW very strong –
20–44 10.6 y=14.38x–0.23, R²=0.336 DW moderate –
45–64 44.0 y=42.90x0.018, R²=0.070 UW weak –
65+ 45.2 y=43.09x0.030, R²=0.113 UW weak –
–




62.2 y=58.69x0.038, R²=0.237 UW moderate –
C51 1.5 y=1.146x0.068, R²=0.005 UW barely –
C52 0.4 y=0.305x0.227, R²=0.226 UW moderate –
C53 9.2 y=7.341x0.147, R²=0.185 UW moderate –
C54 15.2 y=18.60x–0.15, R²=0.410 DW moderate –
C55 0.4 y=0.790x–0.13, R²=0.094 DW weak –
C56 10.9 y=13.48x–0.16, R²=0.193 DW moderate –
C57 0.2 y=2.283x–0.93, R²=0.636 DW strong –
dence rate of malignant neoplasms of the cervix uteri
(C53, 13.0/100,000, SD±2.63, CI 7.82–18.13, Table 3)
showed a weak upward trendline (R2=0.050). However,
when compare trendlines in different age groups, a sig-
nificant strong upward trendline exist in the age group
65+ years (R2=0.566, t(7)=3.021, p<0.02) and a moder-
ate downward trendline in the age group 20–44 years
(R2=384). Malignant neoplasm of other and unspecified
female genital organs (C57) showed a significant strong
upward trendline (R2=0.773, t(2)=2.609, p<0.05) re-
lated with a small and intermittent, incidence rate (de-
grees of freedom=2).
The overall mortality rate from breast cancer was
29.6/100,000 with a significant strong upward trendline
(R2=0.656, t(7)=3.653, p<0.01, Table 4). This upward
trendline is most influenced by the mortality rates of pa-
tients aged 65+ years (R2=0.676, t(7)=3.558, p<0.01).
There was a strong increase in the mortality rate con-
sidering all cancer sites of the C51-C58 cancer group
(R2=0.871, t(7)=6.874, p<0.01, Table 4) directly influ-
enced by mortality rates of patients 45–64 years with ma-
lignant neoplasms of the cervix uteri and (C53) and ma-
lignant neoplasm of ovary (C56).
Five year relative survival rate
The 5-year relative survival rate from breast cancer
was 64.2%. This cancer site implied a small difference in
survival in age groups 20–44 and 45–64 (76.8% and
76.4%, respectively). In age group 65+ the survival rate
was much lower, 49.9% (Table 5A). Within C51-C58 can-
cer group, malignant neoplasm of ovary (C56) was de-
noted by the lowest survival rate, only 43.0%. The differ-
ence between age groups in the survival rate from the
C56 cancer site was great and rate varied a lot: age
groups 20–44, 45–64 and 65+ revealed 5-year relative
survival rates of 80.1%, 57.1% and 20.4%, respectively.
Neither cancer sites showed no significant upward or
downward trendline (Table 5B). C50 and C56 featured
moderate and weak upward trendline (R2=0.180 and
R2=0.096, respectively), while C53 and C54 showed weak
and moderate downward trendline (R2=0.127 and R2=
0.251, respectively). Power mortality rates of C53 and
C54 compared to C56 creates a non significant strong up-
ward trendline for the entire group of cancer C51–C58
(R2=0.569, t(7)=1.999, p>0.05)
Age distribution
The age distribution at diagnosis of breast cancer
(C50), cervix uteri (C53), corpus uteri (C54) and ovary
(C56) cancer sites differ from the respective age distribu-
tion at death. Although the age distribution at diagnosis
of the C50 cancer site was rather similar in age groups
45–64 and 65+ (47.3% and 43.6%, respectively), there
were much more patients who died from this cancer aged
65+ than aged between 45 and 64 (68.8% and 27.4%, re-
spectively) showing a moderate upward trendlines (Ta-
bles 6A and 7A). The proportion of patients with C53
cancer site aged 65+ at diagnosis was 34.3% while the
proportion of female patients of the same age at deaths
was much higher, 58.0%. It was similar to the cancer
sites C54 and C56.
Considering age distribution, there was a big differ-
ence between the 65+ age group and other age groups.
Patients with breast cancer (C50), malignant neoplasm
of the corpus uteri (C54) and malignant neoplasm of the
ovary (C56) mostly died at the age of 65+ (68.8%, 79.0%
and 66.0%, respectively, Figure 1). One needs to single
out malignant neoplasms of the cervix uteri (C53) which
entailed the fact that the 9.0% of patients died at the age
from 20 to 44 (the highest percentage in this age group
among C51-C58 cancer sites, (too small number of cases
for C55)).
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TABLE 6C. The age group proportion (%) of each cancer sites
Age groups
ICD-10 0–44 45–64 65+ All ages
C50 9.2 47.3 43.6 100.0 62.2 –
C51 13.2 23.7 63.2 4.0 –
C52 11.1 44.4 44.4 0.9 –
C53 28.7 37.0 34.3 24.2 –
C54 5.5 38.6 55.9 40.1 –
C55 10.0 0.0 90.0 1.1 –
C56 12.0 43.1 44.9 28.9 –
C57 0.0 50.0 50.0 0.6 –
C58 0.0 100.0 0.0 0.1 –
C51-C58 13.4 38.7 47.9 100.0 37.8 –
C50-C58 10.8 44.0 45.2 100.0 –
R – Relationship, COD(S) – Coefficient of determination (strength), N/A – not available, DW – downward, UW – upward, »–« – to small
data number or no significant (p>0.05), OIR – overall incidence rate
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TABLE 7
THE AGE DISTRIBUTION AT DEATH FOR MALIGNANT NEOPLASMS OF BREAST AND FEMALE GENITAL ORGANS
(C50, C51-C58) IN THE OBC, PERIOD 2001–2009
TABLE 7A. Age group distribution (%) at death for cancer sites C50-C58
ICD-10 Age group OMR COD(S) Trendline Strength Trend t-Test
C50 20–44 3.8 y=4.983x–0.26, R²=0.125 DW weak –
45–64 27.4 y=35.01x–0.18, R²=0.189 DW moderate –
65+ 68.8 y=60.76x0.076, R²=0.266 UW moderate –
C51 45–64 6.9 N/A – – –
65+ 93.1 y=100, R²=–6E–1 DW barely –
C52 45–64 100.0 N/A – – –
C53 20–44 9.0 y=23.85x–0.46, R²=0.529 DW strong –
45–64 33.0 y=27.76x0.110, R²=0.065 UW weak –
65+ 58.0 y=57.45x–0.00, R²=0.001 DW barely –
C54 20–44 2.7 y=2.338x0.794, R²=0.906 UW very strong t(1)=3.104, p<0.02
45–64 18.3 y=39.00x–0.57, R²=0.361 DW moderate –
65+ 79.0 y=65.99x0.118, R²=0.256 UW moderate –
C55 20–44 10.0 N/A – – –
65+ 100.0 N/A – – –
C56 20–44 4.4 y=3.789x0.226, R²=0.215 UW moderate –
45–64 29.6 y=13.22x0.523, R²=0.420 UW moderate –
65+ 66.0 y=79.38x–0.16, R²=0.354 DW moderate –
C57 45–64 16.7 N/A – – –
65+ 83.3 y=100, R²=–1E–1 DW barely –
C51-C58 20–44 4.5 y=6.292x–0.24, R²=0.096 DW weak –
45–64 24.6 y=21.81x0.066, R²=0.033 UW weak –
65+ 70.9 y=73.05x–0.02, R²=0.036 DW weak –
C50-C58 20–44 4.1 y=4.317x–0.14, R²=0.024 DW barely –
45–64 26.2 y=28.56x–0.06, R²=0.060 DW weak –
65+ 69.7 y=66.68x0.027, R²=0.080 UW weak –




54.2 y=49.93x0.051, R²=0.189 UW moderate –
C51 2.5 y=1.369x0.290, R²=0.095 UW weak –
C52 0.2 N/A – N/A –
C53 8.5 y=5.319x0.272, R²=0.190 UW moderate –
C54 15.9 y=14.78x0.028, R²=0.005 UW barely –
C55 0.9 y=1.125x0.075, R²=0.012 UW barely –
C56 17.4 y=24.30x–0.24, R²=0.466 DW moderate t(7)=2.471, p<0.05
C57 0.5 y=1.096x–0.23, R²=0.825 DW very strong t(4)=4.342, p<0.01
TABLE 7C. The age group proportion (%) of each cancer sites
Age groups
ICD-10 0–44 45–64 65+ All ages
C50 3.8 27.4 68.8 100.0 54.2 –
C51 0.0 6.9 93.1 5.4 –
C52 0.0 100.0 0.0 0.4 –
C53 9.0 33.0 58.0 18.7 –
C54 2.7 18.3 79.0 34.7 –
C55 10.0 0.0 90.0 1.9 –
C56 4.4 29.6 66.0 37.9 –
C57 0.0 16.7 83.3 1.1 –
C51-C58 4.5 24.6 70.9 100.0 45.8 –
C50-C58 4.1 26.2 69.7 100.0 –
R – Relationship, COD(S) – Coefficient of determination (strength), N/A – not available, DW – downward, UW – upward, »–« – to small
data number or no significant (p>0.05), OMR – overall mortality rate
Cancer patient hospitalization
In the 2001–2009 period, a total of 1,561 females were
diagnosed with the breast cancer C50 and they were ad-
mitted to the OBC hospitals 2,850 times where they
spent a total of 34,607 days (Tables 10). An average pa-
tient was admitted to hospital 1.8 times during the
course of their illness (Table 8) with a significant strong
downward overall length of stay in hospital (OLOSH)
trendline (R2=0.716, t(7)=2.717, p<0.05) of 12.1 days
(Table 10). Comparing the number of hospital admis-
sions (NOAH) and the LOSH, females aged 65+ spent on
average 14.5 days in hospital, which is 4.7 days more
than females aged 20–44 and 3.8 days more than females
aged 45–64. The LOSH went down in all age groups, and
very strong in age groups 65+ (R2=0.809, t(7)=3.641,
p<0.01). In the same period, the LOSH of females diag-
nosed with C50 cancer declined significant sharply (R2=
0.716, t(7)=2.713, p<0.05)), but without change in the
NOAH (R2=0.025, barely upward trendline). The great-
est share in all hospitalizations (49.1%) referred to fe-
males aged 45–64.
A total of 949 females were diagnosed with the C51-
C58 cancer group and they were admitted to the OBC
hospitals 2,402 times where they spent a total of 35,882
days. An average patient was admitted to hospital 2.5
times (Table 8) during the course of their illness with a
non significant moderate downward LOSH trendline
(R2=0.327) of 14.9 days (Table 10). Among the most com-
mon cancer site in this group, the total number of patient
with C53, C54 and C56 were 230, 381 and 274, respec-
tively; they were admitted to the OBC hospitals 584, 784
and 883 times, respectively; they spent a total of 8655,
14,519 and 9968 days, respectively; an average hospital
admission per patient were 2.8, 1.9 and 3.1 times, respec-
tively (Table 8); the LOSH were 14.8, 18.5 and 11.3 days,
respectively. Females diagnosed with malignant neoplasms
of the corpus uteri (C54) stayed in hospital longer than
females diagnosed with other cancer sites of this cancer
group (18.5 days, Tables 10). The LOSH trendlines for
C53 and C54 moderately decreased (R2=0.224 and R2=
0.451, respectively), while it moderately increased for
C56 (R2=0.46). Contrary, the NOAH for C53 moderately
increased (R2=374) while it moderately and strongly de-
creased for C54 and C56 (R2=465 and R2=609, respec-
tively).
Discussion
Malignant neoplasms of breast (C50) and female geni-
tal organs (C51-C58) within the OBC female population
accounted for 34.8% (C50 – 21.6%, C51-C58 – 13.2%) of
all newly registered cancer cases in the period from 2001
to 2009. In the same population and period of time, the
proportion of C50-C58 cancer group in all cancer cases at
death amounted to 35.5% (C50 – 17.6%, C51-C58 – 14.9%)32.
Breast cancer
According to the data stated in this article, incidence
rate of breast cancer in the OBC decreased in the period
2001–2009. The overall incidence rate resembles the Cro-
atian average and way exceeds the corresponding Cen-
tral and Eastern Europe incidence rates, but is still bel-
low the Northern Europe ones33,34. A study on the breast
cancer incidence in 35 countries (mostly European ones)
from 1990 to 2002 has revealed that the incidence rate
had an upward trend within that period of time35. Pursu-
ant to the respective 2012 EUCAN data, most of these
countries are still experiencing a rise in the number of
newly registered breast cancer cases12. Concerning the
same time period, similar data can be found at the na-
tional level too33.
A decline in the breast cancer incidence is undoubt-
edly related to the raised women’s awareness of this ill-
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TABLE 8
THE TREND AND THE AVERAGE NUMBER OF HOSPITAL ADMISSION PER PATIENT FOR MALIGNANT NEOPLASMS OF BREAST AND
FEMALE GENITAL ORGANS (C50, C51-C58) IN THE OBC, PERIOD 2001–2009
ICD10 ONOHA COD(S) Trendline Strength Significant trendline t-Test
C50 1.8 y=2.045x–0.09, R²=0.377 DW moderate –
C51 2.1 y=1.572x0.043, R²=0.009 UW barely –
C52 2.8 y=1.346x0.137, R²=0.010 UW barely –
C53 2.8 y=2.597x0.000, R²=3E–07 DW barely –
C54 1.9 y=1.865x–0.04, R²=0.031 DW weak –
C55 1.3 y=1.224x–0.26, R²=0.160 DW weak –
C56 3.1 y=3.541x–0.15, R²=0.187 DW moderate –
C57 2.0 y=19.60x–1.79, R²=0.983 DW very strong t(2)=10.75, p<0.01
C58 1.3 N/A N/A N/A N/A
C51-C58 2.5 y=2.494x–0.02, R²=0.027 DW barely –
C50-C58 2.1 y=2.24x–0.06, R²=0.249 DW weak –
ONOHA – overall number of hospital admission per patient, DW – downward trendline, UW – uwward trendline, N/A – not available,
R – Relationship, COD(S) – Coefficient of determination (strength), ICD10 – International Statistical Classification of Diseases and Re-
lated Health Problems, 10th Revision, »–« – to small data number or no significant (p>0.05)
ness. For about 20 years, Croatian women have been ex-
posed to necessary information on the need of formal and
informal breast cancer education provided more or less
frequently by various media36. The extent of the effect of
educational programmes on the quality of healthcare and
changes of statistical indicators is best indicated by the
data on the incidence rate in the OBC since the initiation
of the national breast cancer prevention programme in
2006. The incidence rate rose sharply in 2007, then fell to
the 2006 level and has kept falling ever since. Comparing
to the data at the national level37–39, the overall mortality
rate was below the Croatian average in the time24,26,40.
The data of concern is the significant mortality rate up-
ward trend for all age groups and separately for age
group 65+ years (Table 4).
The 5-year relative survival rate from breast cancer
diagnosed among European females from 1995 to 1999
years was (5 years earlier) higher by 3.6 of percent points
then appertaining survival rate in the OBC in the period
2001–2005 (64.2%)5. The data of the median age at diag-
nosis were almost the same in the USA, Croatia and in
the OBC (61, 61.5 and 61.5 years, respectively), while the
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TABLE 9
THE TREND AND THE AVERAGE NUMBER OF ADMISSION IN HOSPITAL FOR MALIGNANT NEOPLASMS OF BREAST
AND FEMALE GENITAL ORGANS (C50, C51-C58) IN THE OBC, PERIOD 2001–2009
Age group
ICD-10 Parameters 0–19 20–44 45–64 65+ All ages
C50 ONOAH – 32.7 155.4 128.6 316.7
Trendline – DW UW UW UW
Strength – weak barely weak barely
C51 ONOAH – 0.4 2.9 6.6 9.9
Trendline – UW UW UW UW
Strength – strong moderate moderate moderate
C52 ONOAH – 0.1 0.9 1.7 2.7
Trendline – – UW UW UW
Strength – – barely weak moderate
C53 ONOAH 0.1 15.2 26.8 22.8 64.9
Trendline – DW UW UW UW
Strength – barely moderate moderate moderate
C54 ONOAH – 5.0 34.4 47.7 87.1
Trendline – DW DW DW DW
Strength – strong moderate weak moderate
C55 ONOAH – 0.2 0.3 1.4 2.0
Trendline – – UW DW DW
Strength – – – moderate moderate
C56 ONOAH 0.8 12.6 50.2 34.6 98.1
Trendline – DW DW DW DW
Strength – barely moderate barely strong
C57 ONOAH 0.1 – 1.1 0.8 2.0
Trendline – – UW UW DW
Strength – – weak moderate weak
C58 ONOAH – – 0.1 0.1 0.2
C51-C58 ONOAH 1.0 33.6 116.8 115.6 266.9
Trendline UW DW DW UW DW
Strength moderate moderate moderate barely strong
C50-C58 ONOAH 1.0 66.2 272.2 244.1 583.6
Trendline UW DW DW UW DW
Strength moderate moderate weak weak weak
ONOAH – overall number of admissions in hospital, UW – upward, DW – downward, ICD10 – International Statistical Classification
of Diseases and Related Health Problems, 10th Revision, t – significance of the coefficient of determination
figures on the median age at death in the USA were dif-
ferent from those collected in the OBC (68 and 69.1
years, respectively)13,14.
Between 1981 and 2000, the length of stay of patient
with breast cancer in Canada hospitals declined from 26
days to 9.4 days (almost 64%, each year 3.2%) and the
number of hospital admissions during that period re-
main the same41. In the OBC, the length of stay over the
9-year period declined by 0.6% each year. Compare to the
Canadian data referring to the year 2000, the average
length of stay in OBC (14.7 days) was 5.3 days longer.
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TABLE 10
THE AGE GROUP AND CORRESPONDING TREND OF THE OVERALL LENGTH OF STAY IN HOSPITAL FOR MALIGNANT
NEOPLASMS OF BREAST AND FEMALE GENITAL ORGANS (C50, C51-C58) IN THE OBC, PERIOD 2001–2009
Age group
ICD10 Parameters 0–19 20–44 45–64 65+ All ages
C50 OLOSH – 9.8 10.7 14.5 12.1
Trendline – DW DW DW DW
Strength – strong weak very strong strong
Trendline (t) – t (7)=2.801, p<0.05 t (7)=0.084, p>0.05 t (7)=3.641, p<0.01 t (7)=2.713, p<0.05
C51 OLOSH – 19.5 17.2 24.5 22.1
Trendline – DW UW UW DW
Strength – moderate barely weak weak
C52 OLOSH – 7.0 17.4 8.5 11.4
Trendline – – DW DW UW
Strength – – strong barely barely
C53 OLOSH 3.0 12.0 14.0 17.7 14.8
Trendline – UW DW DW DW
Strength – barely weak strong moderate
C54 OLOSH – 17.1 16.7 20.0 18.5
Trendline – UW DW DW DW
Strength – moderate strong strong moderate
C55 OLOSH – 24.5 14.0 11.1 13.1
Trendline – – DW DW DW
Strength – – moderate strong moderate
C56 OLOSH 13.0 8.6 9.5 14.8 11.3
Trendline – UW UW DW UW
Strength – moderate strong moderate moderate
Trendline (t) – – t (7)=2.420, p<0.05 – –
C57 OLOSH 8.0 – 8.7 23.0 14.2
Trendline – – DW UW UW
Strength – – barely very strong strong
C58 OLOSH – – 2.0 2.0 2.0
C51-C58 OLOSH 11.3 11.7 12.9 18.0 14.9
Trendline UW UW DW DW DW
Strength very strong barely barely moderate moderate
Trendline (t) t (1)=22.34, p<0.01 – – – –
C50-C58 OLOSH 11.3 10.7 11.6 16.2 13.4
Trendline UW DW DW DW DW
Strength very strong moderate weak strong strong
Trendline (t) t (1)=22.34, p<0.01 – – – –
OLOSH – overall length of stay in hospital, UW – upward, DW – downward, ICD10 – International Statistical Classification of Diseases
and Related Health Problems, 10th Revision, t – significance of the coefficient of determination, »–« – to small data number or no sig-
nificant (p>0.05)
In summary, female patients develop breast cancer
and die both later and later, the incidence rate rises
strongly until 2007, and then decline, five-year relative
survival rate is extended and declined the number of hos-
pitalizations per year, the number of hospitalizations per
person/year and the length of hospitalization per year.
Negative data is that the mortality rate increases signifi-
cantly. The implementation and consolidation of female’s
awareness of these cancers and relating early diagnostic
activities within the OBC population seem to be the most
effective ways to reduce the appertaining risks and thus
to encourage changes in the lifestyle.
Ovarian (C56) and endometrial cancer (C54)
In the OBC, the overall incidence and mortality rate
from ovarian and endometrial cancer exceeded the relat-
ing EU rates. The incidence rate for endometrial cancer
(C54) decreased in each age group as well as in all age’s
groups together. In the same period, the incidence rate of
the C54 cancer site fell bellows the Croatian average40.
The overall incidence rate of ovarian cancer (C56) was
slightly below the Croatian average (Table 3). The inci-
dence rate of the C56 cancer site moderate decreased in
age groups 45–64 and 65+ years. Similarly to the situa-
tion with breast cancer, propaganda in public media and
education of women exercises great influence on the de-
cline of this incidence rate. Unfortunately, the mortality
rates show a moderate increase for C54 cancer due to an
increase in mortality rate in the age group 65+ years
(Table 4). The mortality rate is nearly twice as high as in
Europe. The 5-year relative survival rate from endome-
trial cancer (C54) in the OBC of 57.4% is well below the
USA and EU rates (83% and 78%, respectively) whereas
the survival rate from ovarian cancer of 43.0% is very
close to the USA average (46%) and higher than the re-
spective EU rate (36.3%)19,42,43. Comparing to the aver-
age length of stay in one hospital in the UK due to ovar-
ian cancer (8.5 days)44, female patients with the same
cancer spent 2.7 days more in the OBC hospitals (11.3
days) for the same reason. Compare to the Australian av-
erage, the length of stay in the OBC hospitals due to
endometrial cancer was longer by 12.8 days45.
In summary, female patients develop endometrial
cancer (C54) and die both later and later, the incidence
rate decreased and declined the number of hospitaliza-
tions per year, the number of hospitalizations per per-
son/year and the length of hospitalization per year. Nega-
tive data: the mortality rate and 5-year relative survival
rates decreased. Female patients with ovarian cancer
(C56) showed negative trendline for median age at diag-
nosis and at death and upward mortality rate.
Cervical cancer (C53)
In the OBC, the overall incidence rate of cervical can-
cer (13.0/100,000) slightly increased in 2001–2009 pe-
riod. It corresponded to Central, Eastern and Western
European incidence rates and to the Croatian average.
The overall mortality rate of 5.0/100,000 was lower then
in Central and Eastern Europe (8.7 and 6.2/100,000, re-
spectively), and lower than the Croatian average15,22,24.
In the OBC, the incidence rate of the age group 45–64 ex-
perienced almost a threefold increase as well as a twofold
increase in the age group 65+ years (Figure 7). Cur-
rently, there is no information which might, to some ex-
tent, explain the rise in the mortality rate. Compared to
the 5-year relative survival rate in the EU5, the respec-
tive rate was higher in the OBC (62.6% and 66.1%, re-
spectively). Compare to the length of stay in hospitals in
Spain (15.2 days), females with cervical cancer in the
OBC stayed shorter in hospital on average by 14.8 days47.
A distinctive reduction in the incidence of cervical cancer
over the past two decades in some European countries
and North America suggests that in the OBC there is still
no widespread screening and early treatment of pre-in-
vasive lesions. Cervical cancer screening programs were
first established in Croatia in the 2012.
In summary, in female patients with cervical cancer
(C53) the median age at diagnosis was significantly shifts
the older age, dies later, declined the number of hospital-
izations per person/year and the length of hospitalization
per year. Unfortunately, the 5-year relative survival rates
decreased.
Implementation and consolidation of women’s aware-
ness of these cancers and relating early diagnostic activi-
ties within the OBC population seem to be the most ef-
fective ways to reduce the appertaining risks and thus to
encourage changes in the lifestyle.
Limitations
Patients who were treated outside the hospitals in the
OBC are not registered with the IPHO. Despite the ef-
forts to obtain this information (it exist at the national
level) in its original form, the authors were unable to ob-
tain those data for unknown reasons. Therefore, these
data on cancer in the OBC may differ from official state
data on cancer in the OBC.
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Fig. 1. The age distribution for malignant neoplasms of breast and female genital organs (C50, C51-C58) in the period 2001–2009.
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RAK DOJKE I @ENSKIH SPOLNIH ORGANA U OSJE^KO-BARANJSKOJ @UPANIJI, HRVATSKA
S A @ E T A K
Rak dojke (C50) i rak `enskih spolnih organa (C51-C58) su me|u naju~estalijim neoplazmama u `ena u razvijenim
zemljama. Zavod za javno zdravstvo Osje~ko-Baranjske `upanije u suradnji s razli~itim `upanijskim ustanovama vodi
podatke oboljelih od raka s podru~ja Osje~ko-Baranjske `upanije (OBC). Cilj je ovoga ~lanka dati informaciju o raku
dojke i raku `enskih spolnih organa u vremenu od 2001–2009 godine. Ovo je ujedno i prvi ~lanak o ovim sijelima raka na
razini jedne `upanije u Hrvatskoj. ^lanak obra|uje podatke o incidenciji i mortalitetu, dobnoj distribuciji, srednjoj dobi
u trenutku dijagnoze i smrti, pre`ivljavanje i du`inu hospitalizacije oboljelih od ove vrste raka za razdoblje od 1996 –
2010. U OBC prosje~na stopa incidencije u {estogodi{njem razdoblju za rak dojke, u{}a maternice, tijela maternice i
jajnika (kori{tena je EU standardna populacija) je bila 82,9, 13,0, 19,0 i 14,5/100,000. Pojedina~no promatrane, stope za
svaku vrstu raka padaju tijekom promatranog razdoblja, osim za rak dojke. Stopa incidencije za rak dojke u OBC sli~na
je hrvatskom prosjeku, nadma{uje stopu incidencije u Srednjoj i Isto~noj Europi, ali je ni`a od one u Sjevernoj Europi. U
OBC prosje~na stopa smrtnosti u {estogodi{njem razdoblju za rak dojke, u{}a maternice, tijela maternice i jajnika je
bila 29,6, 5,0, 8,1 i 9,6/100,000 te sve stope raka pokazuju uzlazni trend. 5-godi{nje relativno pre`ivljavanje oboljelih od
raka dojke, u{}a maternice, tijela maternice i jajnika u vremenu od 2001–2005 godine je 64,2%, 66,1%, 57,4% i 43,0%.
Prosje~na srednja dob u trenutku postavljanja dijagnoze raka dojke, u{}a maternice, tijela maternice i jajnika je bila
61,9, 56,4, 66,4 i 60,8 godina. Srednja dob u trenutku smrti oboljelih od raka dojke, u{}a maternice, tijela maternice i
jajnika je bila 68,7, 65,7, 70,3 i 67,6 godina. U devetogodi{njem razdoblju prosje~na du`ina boravka oboljelih od raka
dojke, u{}a maternice, tijela maternice i jajnika je bila 12,1, 14,8, 18,5 i 11,3 dana. Du`ina hospitalizacije oboljelih od
raka pada za sva sijela osim za rak jajnika. Podizanje svijesti `ena OBC o raku dojke i raku `enskih spolnih organa,
preventivnim pregledima, va`nosti rane dijagnoze i promjene na~ina `ivota su naju~inkovitiji na~in smanje rizike od
raka, odnosno njegovih posljedica na zdravlje.
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